Literature DB >> 22246618

Uterine serous carcinoma: increased familial risk for lynch-associated malignancies.

Summer B Dewdney1, Nora T Kizer, Abegail A Andaya, Sheri A Babb, Jingqin Luo, David G Mutch, Amy P Schmidt, Louise A Brinton, Russell R Broaddus, Nilsa C Ramirez, Phyllis C Huettner, Donald Scott McMeekin, Kathleen Darcy, Shamshad Ali, Patricia L Judson, Robert S Mannel, Shashikant B Lele, David M O'Malley, Paul J Goodfellow.   

Abstract

Serous uterine cancer is not a feature of any known hereditary cancer syndrome. This study evaluated familial risk of cancers for patients with serous uterine carcinoma, focusing on Lynch syndrome malignancies. Fifty serous or mixed serous endometrial carcinoma cases were prospectively enrolled. Pedigrees were developed for 29 probands and tumors were assessed for DNA mismatch repair (MMR) abnormalities. Standardized incidence ratios for cancers in relatives were estimated. A second-stage analysis was undertaken using data from Gynecologic Oncology Group (GOG)-210. Incidence data for cancers reported in relatives of 348 patients with serous and mixed epithelial and 624 patients with endometrioid carcinoma were compared. Nineteen of 29 (65.5%) patients in the single-institution series reported a Lynch-related cancer in relatives. Endometrial and ovarian cancers were significantly overrepresented and a high number of probands (6 of 29, 20.7%) reported pancreatic cancers. None of the probands' tumors had DNA MMR abnormalities. There was no difference in endometrial or ovarian cancer incidence in relatives of serous and endometrioid cancer probands in the case-control study. Pancreatic cancers were, however, significantly more common in relatives of patients with serous cancer [OR, 2.39; 95% confidence interval (CI), 1.06-5.38]. We identified an excess of endometrial, ovarian, and pancreatic cancers in relatives of patients with serous cancer in a single-institution study. Follow-up studies suggest that only pancreatic cancers are overrepresented in relatives. DNA MMR defects in familial clustering of pancreatic and other Lynch-associated malignancies are unlikely. The excess of pancreatic cancers in relatives may reflect an as yet unidentified hereditary syndrome that includes uterine serous cancers.

Entities:  

Mesh:

Year:  2012        PMID: 22246618      PMCID: PMC3294192          DOI: 10.1158/1940-6207.CAPR-11-0499

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  44 in total

1.  Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.

Authors:  P Ghiorzo; V Pensotti; G Fornarini; S Sciallero; L Battistuzzi; F Belli; L Bonelli; G Borgonovo; W Bruno; A Gozza; S Gargiulo; L Mastracci; S Nasti; G Palmieri; F Papadia; L Pastorino; A Russo; V Savarino; L Varesco; L Bernard; G Bianchi Scarrà
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

2.  p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.

Authors:  W Zheng; P Cao; M Zheng; E E Kramer; T A Godwin
Journal:  Gynecol Oncol       Date:  1996-05       Impact factor: 5.482

3.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.

Authors:  Heather Hampel; Wendy Frankel; Jenny Panescu; Janet Lockman; Kaisa Sotamaa; Daniel Fix; Ilene Comeras; Jennifer La Jeunesse; Hidewaki Nakagawa; Judith A Westman; Thomas W Prior; Mark Clendenning; Pamela Penzone; Janet Lombardi; Patti Dunn; David E Cohn; Larry Copeland; Lynne Eaton; Jeffrey Fowler; George Lewandowski; Luis Vaccarello; Jeffrey Bell; Gary Reid; Albert de la Chapelle
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma.

Authors:  J P Geisler; J I Sorosky; H L Duong; T E Buekers; M J Geisler; A K Sood; B Anderson; R E Buller
Journal:  Gynecol Oncol       Date:  2001-12       Impact factor: 5.482

5.  Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.

Authors:  G Larry Maxwell; Chunqiao Tian; John Risinger; Carol L Brown; G Scott Rose; J Tate Thigpen; Gini F Fleming; Holly H Gallion; Wendy R Brewster
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

Review 6.  Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.

Authors:  Larissa A Meyer; Russell R Broaddus; Karen H Lu
Journal:  Cancer Control       Date:  2009-01       Impact factor: 3.302

7.  An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

Authors:  Amanda Nickles Fader; David Starks; Paola A Gehrig; Angeles Alvarez Secord; Heidi E Frasure; David M O'Malley; Erin R Tuller; Peter G Rose; Laura J Havrilesky; Kathleen N Moore; Warner K Huh; Allison E Axtell; Joseph L Kelley; Kristine M Zanotti
Journal:  Gynecol Oncol       Date:  2009-08-26       Impact factor: 5.482

8.  Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

Authors:  Stefanie M Ueda; Daniel S Kapp; Michael K Cheung; Jacob Y Shin; Kathryn Osann; Amreen Husain; Nelson N Teng; Jonathan S Berek; John K Chan
Journal:  Am J Obstet Gynecol       Date:  2008-02       Impact factor: 8.661

9.  Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer.

Authors:  Jennifer Ivanovich; Sheri Babb; Paul Goodfellow; David Mutch; Thomas Herzog; Janet Rader; Alison Whelan
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

10.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Authors:  C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more
  5 in total

1.  BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.

Authors:  Kathryn P Pennington; Tom Walsh; Ming Lee; Christopher Pennil; Akiva P Novetsky; Kathy J Agnew; Anne Thornton; Rochelle Garcia; David Mutch; Mary-Claire King; Paul Goodfellow; Elizabeth M Swisher
Journal:  Cancer       Date:  2012-07-18       Impact factor: 6.860

2.  Cancer susceptibility gene mutations in type I and II endometrial cancer.

Authors:  Beverly Long; Jenna Lilyquist; Amy Weaver; Chunling Hu; Rohan Gnanaolivu; Kun Y Lee; Steven N Hart; Eric C Polley; Jamie N Bakkum-Gamez; Fergus J Couch; Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2018-10-26       Impact factor: 5.482

Review 3.  Controversies in the Management of Early-stage Serous Endometrial Cancer.

Authors:  Alyssa Larish; Andrea Mariani; Carrie Langstraat
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

4.  Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

Authors:  Brent J Tierney; Georgia A McCann; Shan Naidu; Kellie S Rath; Uksha Saini; Ross Wanner; Periannan Kuppusamy; Adrian Suarez; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2014-07-16       Impact factor: 5.482

Review 5.  Therapeutic role of curcumin and its novel formulations in gynecological cancers.

Authors:  Mohammad Hossein Pourhanifeh; Maryam Darvish; Javad Tabatabaeian; Mahboobeh Rabbani Fard; Reza Mottaghi; Mohammad Javad Azadchehr; Moghaddaseh Jahanshahi; Amirhossein Sahebkar; Hamed Mirzaei
Journal:  J Ovarian Res       Date:  2020-11-04       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.